Galera Therapeutics, Inc.
Galera Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for difficult-to-treat breast cancers. After acquiring Nova Pharmaceuticals in late 2024, the company shifted its strategy toward a pan-NOS inhibitor program and retained two SOD mimetic assets from its earlier portfolio.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage nitric oxide synthase inhibitor being developed for advanced breast cancer indications.
Legacy small-molecule dismutase mimetics, including avasopasem, supported mainly through clinical supply commitments.
Company-run and investigator-sponsored trial support, including drug supply, protocol support and development oversight.
Asiakkaat
Galera does not sell commercial products today; its primary counterparties are clinical investigators, research hospitals, and consortium partners running oncology trials. Future customers, if development succeeds, would be oncology specialists and cancer centers treating advanced breast cancer patients. The company also relies on grant-funded academic collaborators and contract research organizations to execute studies.
Academic hospitals and investigators receive drug supply and study support for NIH-funded breast cancer trials.
Collaborative networks such as I-SPY 2 help test the pan-NOS inhibitor in broader TNBC populations.
Cancer centers are the eventual end users if the company secures regulatory approval and commercialization.
CROs, CMOs and consultants are paid to run studies, manufacture materials and support development.
Strategia
The company’s strategy changed materially after the Nova acquisition, with a new focus on advanced breast cancer programs built around a pan-NOS inhibitor. Near term, Galera is prioritizing clinical readouts, investigator-sponsored studies, and low-cash-burn development supported by grants and existing drug supply. The goal is to preserve capital while advancing proof-of-concept data that could support partnering or future financing.
This is the lead asset and the main source of future value creation.
Broader TNBC activity could enlarge the addressable patient population and improve partnering appeal.
The company has limited cash and needs to extend runway while advancing clinical milestones.
Maantiede
Galera is headquartered in the United States and its development activity is centered on U.S. clinical sites, including Houston Methodist in Texas. The company’s current footprint is therefore concentrated in U.S.-based research and trial execution rather than commercial sales. Its OTCQB listing also keeps the company tied to U.S. capital markets for funding.
Riskit
Galera remains a high-risk clinical-stage biotech with no commercial revenue and a heavy dependence on successful trial execution, regulatory outcomes and future financing. The company also faces going-concern and dilution risk because its cash resources are limited and development programs are still early. As with other oncology developers, clinical failure, safety issues, enrollment delays and partner dependence can materially impair value.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Matala
The company’s value depends on positive results from early-stage oncology trials.
Kohdistuu: Lead pan-NOS inhibitor and legacy SOD mimetics
- Going-concern and financing riskVaikutus: KorkeaTodennäköisyys: Korkea
Cash resources are limited and the company may need additional capital before commercialization.
Kohdistuu: Operating runway and future trial funding
- Regulatory and trial execution riskVaikutus: KorkeaTodennäköisyys: Matala
Enrollment, protocol changes, safety findings and regulatory requirements can delay or derail studies.
Kohdistuu - Dependence on external collaboratorsVaikutus: Keskitaso
Key studies rely on NIH grants, investigators and consortium partners rather than fully internal execution.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical costs are expensed as incurred, so trial timing directly affects reported losses.
Vaikutus: Quarterly volatility in operating expense and net loss
Management must estimate whether existing cash is sufficient to fund operations for the next 12 months.
Vaikutus: Important for liquidity disclosure and financing risk
Equity awards are a meaningful non-cash cost for a small biotech company.
Vaikutus: Affects both R&D and G&A expense
The Nova transaction and clinical-stage assets require judgment on fair value and recoverability.
Vaikutus: Could affect intangible asset carrying values and future impairment risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Olema Pharmaceuticals, Inc.
OLMA · Pharmaceutical Preparations
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for…
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Päivitetty: 24.9.2026